5-ALA, 5-aminolevulinic acid; 5-FU, 5-fluorouracil; ALKP, alkaline phosphatase; ALT, alanine aminotransferase; APCs, antigen-presenting cells; AST, aminotransferase; ATP, adenosine triphosphate; AUC, area under curves; Bioresponsive; CLSM, confocal laser scanning microscope; CPT-11, irinotecan; CRE, creatinine; CRT, calreticulin; Ce6, chlorin e6; Chemotherapy; DAMPs, damage-associated molecular patterns; DCs, dendritic cells; DDSs, drug delivery systems; DLN, draining lymph nodes; DM NGs, doxorubicin-based mannose nanogel; DOC, docetaxel; DOX, doxorubicin; DTT, d,l-dithiothreitol; Doxorubicin; FCM, flow cytometry; FDA, Fluorescein diacetate; GEM, gemcitabine; GSH, glutathione; H&E, hematoxylin-eosin; HCPT, 10-hydroxy camptothecin; HCT, hematocrit; HGB, hemoglobin concentration; HMGB1, high migrating group box 1; ICB, immune checkpoint blockade; ICD, immunogenic cell death; ICG, indocyanine Green; IHC, immunohistochemistry; ITM, immunosuppressive tumor microenvironment; Immunogenic cell death; Immunotherapy; LDH, lactate dehydrogenase; LYM, lymphocyte ratio; MAN, mannose; MCHC, mean corpuscular hemoglobin concentration; MCSs, multicellular spheroids; MFI, mean fluorescence intensity; MPV, mean platelet volume; Mannose; NGs, nanogels; Nanogel; OXA, oxaliplatin; P18, purpurin 18; PDI, polydispersity index; PLT, platelets; PTX, paclitaxel; Prodrug; RBC, red blood cell count; RDW, variation coefficient of red blood cell distribution width; TAAs, tumor-associated antigens; TAM, tumor-associated macrophages; TGF-ß, transforming growth factor-ß; TMA, tissue microarrays; TME, tumor microenvironment; Urea, urea nitrogen; WBC, white blood cell count; irAEs, immune-related adverse events